Related news from
Wed, 24 Apr 2024 20:00:00 +0000	Madrigal Statement on the Passing of Dr. Stephen Harrison CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen’s family for their loss. Stephen was a colleague and friend to so many of us at Madrigal. He worked tirelessly to improve the lives of people with nonalcoholic steatohepatitis (NASH), and his contributions to the field will touch countless families across the globe for decades to come. So many of the recent in
Tue, 23 Apr 2024 12:00:00 +0000	Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceut
Tue, 16 Apr 2024 20:05:00 +0000	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 7 new employees, in each case with a grant date of April 15, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The equity a
Mon, 15 Apr 2024 20:28:54 +0000	Latest Insider Selling in April 2024: 10 Stocks to Watch In this article, we will take a detailed look at Latest Insider Selling in April 2024: 10 Stocks to Watch. For a quick overview of the 5 such stocks, read our article Latest Insider Selling in April 2024: 5 Stocks to Watch. Wall Street analysts and wise investors often keep a close eye on insider buying and selling, […]
Tue, 09 Apr 2024 12:00:00 +0000	Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis Rezdiffra Rezdiffra product image Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s specialty pharmacy network CONSHOHOCKEN, Pa., April 09, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Rezdiffra (resmetirom) is now available in
Fri, 05 Apr 2024 11:15:00 +0000	Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics These businesses should see good times ahead.
Thu, 04 Apr 2024 05:55:10 +0000	Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares James Daly, Director of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), has sold 32,489 shares of the company on April 2, 2024, according to a recent SEC Filing.
Thu, 04 Apr 2024 05:54:45 +0000	Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares Richard Levy, Director of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), has sold 11,000 shares of the company on April 1, 2024, according to a recent SEC Filing.
Thu, 04 Apr 2024 05:54:35 +0000	Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focusing on the development and commercialization of novel therapies that address unmet needs in the treatment of liver and cardiovascular diseases, has reported a significant insider sell according to the latest SEC filings.
Wed, 03 Apr 2024 12:45:00 +0000	1 No-Brainer Growth Stock to Buy Now This liver-disease specialist might be significantly undervalued.
Tue, 02 Apr 2024 01:09:10 +0000	The 3 Best Biotech Stocks to Buy in April 2024 Right now, biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. All of this is thanks to new innovation, millions of retiring baby boomers, demand for better care, pharmaceutical companies nearing patent expirations, a resurgence of mergers and acquisitions, and even new treatments that’ll help you shed weight. Look at obesity drug stocks, for example. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Si
Fri, 29 Mar 2024 13:00:00 +0000	Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals Both stocks are pretty risky, but one of them more so than the other.
Fri, 29 Mar 2024 08:43:00 +0000	Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?
Tue, 26 Mar 2024 13:53:00 +0000	Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock This biotech just got clearance to dive into a deep ocean of a market.
Fri, 22 Mar 2024 10:15:00 +0000	This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? The mid-cap biotech has succeeded where many others failed.
Tue, 19 Mar 2024 09:50:00 +0000	Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? Madrigal has one key advantage over its two huge potential future rivals.
Tue, 19 Mar 2024 03:58:00 +0000	Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 750,000 shares of its common stock at a public offering price of $260.0000 per share, and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of common stock at a price of $259.9999 per pre-funded warra
Tue, 19 Mar 2024 00:01:33 +0000	7 Biotech Stocks Ready to Ride the Sector’s Resurgence Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation. First, the hard data supports bullishness in biotech stocks. According to Grand View Research, the underlying global industry reached a valuation of $1.55 trillion last year. Moving forward, experts project that the sector will expand at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030. At the culmination point, the space may be worth $3.88 trillion. Second, a sector r
Mon, 18 Mar 2024 20:04:00 +0000	Madrigal Pharmaceuticals Announces Proposed Public Offering CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it has commenced an underwritten public offering of $500 million in shares of its common stock and pre-funded warrants to purchase common stock. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold
Mon, 18 Mar 2024 19:15:00 +0000	Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 63 to 83.